reports
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV 25-Jan-2022 / 15:02 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growth Fund...
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV 25-Jan-2022 / 14:56 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growth Fund...
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV 17-Dec-2021 / 16:59 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growth Fund...
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV 14-Dec-2021 / 14:49 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growth Fund...
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group plc 09-Dec-2021 / 14:40 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growth Fund ...
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Clini...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Clinigen Group plc 08-Dec-2021 / 13:52 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growt...
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV 06-Dec-2021 / 13:27 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelverton UK Equity Growth Fund...
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group ...
Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc: Opening Position Disclosure 03-Dec-2021 / 14:19 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: MI Chelver...
Clinigen Launches Malaysia Office to Strengthen Presence in Southeast ...
BURTON-UPON-TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has launched its Malaysian business with an office in Kuala Lumpur. The new office is part of Clinigen’s strategy to expand its footprint in Southeast Asia, an important market for the Group. The Group’s strategy in Malaysia is to become the vendor of choice for the sourcing and supply of medicines to its customers, providing additional infrastructure to support its mission to deliver the right medicine to the right patient and the right time. The immediat...
Clinigen Expands Partnership With Accord Healthcare in Clinical Servic...
BURTON UPON TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service with Accord Healthcare (‘Accord’) into France. Through this arrangement, Clinigen’s CS customers will continue to access the Accord portfolio – both UK and EU packs of product – for their clinical trials worldwide. Clinigen’s CS business and Accord have been partners since 2012 in the delivery of oncology Injectable Products, which are the most widely us...
Clinigen Group: 3 directors bought
Three Directors at Clinigen Group bought 15,716 shares at between 603p and 609p. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Clinigen: IL-2 Plays Role in Emerging TIL Therapies
BURTON UPON TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non -small cell lung cancer (NSCLC).” Ben C. Creelan MD, MS from the Thoracic Oncology, Immunology Program of the Moffitt Cancer and Research Institute presented at the American Association for Cancer Research (AACR) virtual annual meeting on April 28, 2020. Eligibility criteria desc...
 Clinigen and Orphazyme launch an Early Access Program for arimoclomo...
BURTON UPON TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, ‘Orphazyme’), a global biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, to introduce and administer an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C (NPC) in the US. Arimoclomol has received orphan drug, fast track and breakthrough designations from the US Food and Drug Administration (FDA) and has reported positive results fr...
Clinigen Signs Exclusive Distribution Agreement with CHEPLAPHARM to Di...
BURTON UPON TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, and CHEPLAPHARM Arzneimittel GmbH (‘CHEPLAPHARM’), the family-owned pharmaceutical company based in Germany, have signed an exclusive distribution agreement for chemotherapy products Etopophos® and Vepesid® in Australia and New Zealand. CHEPLAPHARM acquired the global rights to the products from Bristol-Myers Squibb (BMS) in August 2018. CHEPLAPHARM has global capabilities in manufacturing and distribution and will continue to supply and pro...
Clinigen Appoints James Meyer as General Manager of Commercial Medicin...
BURTON UPON TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed James (‘Jim’) Meyer as General Manager, Commercial Medicines, US, with immediate effect. Jim Meyer is an accomplished and seasoned executive with nearly 40 years of experience in the pharmaceutical industry, of which included five years at Teva Pharmaceuticals where he led the Oncology New Products Division in the US. As the Oncology Lead, he was responsible for the ...
Clinigen’s Foscavir® gains approval for HHV-6 encephalitis in Japan
BURTON-UPON-TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that Foscavir (foscarnet sodium) has received approval for the treatment of HHV-6 encephalitis from the Ministry of Health, Labour and Welfare (‘MHLW’) in Japan. Approval of the new indication by the MHLW follows reimbursement received in November 2018. Foscavir is the first medicine in the world to receive approval from a Regulatory Authority for the treatment of HHV-6 encephalit...
Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access ...
BURTON UPON TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare and fatal genetic condition of accelerated aging in children that researchers believe is caused by a genetic mutation that results in an ...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
The U.S. has continued to separate itself from broad emerging market and developed international indexes. Thankfully, one positive is that MSCI EM and MSCI EAFE have been able to stabilize from a price perspective despite relative strength weakness vs. MSCI ACWI... see charts below. In today's report we scour the globe for attractive investments in an environment where selectivity is key. • Emerging markets. There is still not much to like about broad EM as the MSCI Emerging Markets index ...
IPN IPSEN SA
EQNR EQUINOR ASA
INFY INFOSYS LIMITED
J2B EXPERIAN PLC
LONN LONZA GROUP AG
ERF ENERPLUS CORPORATION
CLIN CLINIGEN GROUP PLC
HUSKF HUSKY ENERGY INC.
AIA AUCKLAND INTERNATIONAL AIRPORT LIMITED
PMO PREMIER OIL PLC
OXB OXFORD BIOMEDICA PLC
3JDA RIGHTMOVE PLC
NOVO B NOVO NORDISK A/S CLASS B
ALA ALTAGAS LTD.
SOBI SWEDISH ORPHAN BIOVITRUM AB
CJ5A CGI
CPU COMPUTERSHARE LIMITED
CAP CAPGEMINI SE
ABC ABCAM PLC
PXT PAREX RESOURCES INC.
FAE FAES FARMA S.A.
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
KEY. KEYERA CORP.
GUD KNIGHT THERAPEUTICS
BPT BEACH ENERGY LIMITED
4559 ZERIA PHARMACEUTICAL CO. LTD.
COH COCHLEAR LIMITED
FSX FUTURE CORP
9682 DTS CORP.
4812 INFORMATION SERVICES INTERNATIONAL-DENTSU LTD.
6869 SYSMEX CORPORATION
STMN STRAUMANN HOLDING AG
2427 OUTSOURCING INC.
SKIS B SKISTAR AB
NAN NANOSONICS
FLRY3 FLEURY SA
NMC NMC HEALTH PLC
DIM SARTORIUS STEDIM BIOTECH SA
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
7730 MANI
WOR WORLEY LIMITED
7459 MEDIPAL HOLDINGS CORPORATION
9987 SUZUKEN CO. LTD.
8129 TOHO HOLDINGS CO. LTD.
7747 ASAHI INTECC CO. LTD.
2412 BENEFIT ONE INC.
3769 GMO PAYMENT GATEWAY INC.
5020 ENEOS HOLDINGS INC.
DHG DALATA HOTEL GROUP PLC
4503 ASTELLAS PHARMA INC.
POX PANDOX AB CLASS B
AZN ASTRAZENECA PLC
VIFN VIFOR PHARMA AG
145720 DENTIUM
Clinigen signs agreement with Nordic Pharma for aprotinin
BURTON-ON-TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an agreement with Nordic Pharma Ltd. (‘Nordic Pharma’) to manage the supply and distribution of aprotinin in a range of countries in Asia Pacific and South Africa. Aprotinin Injection belongs to a group of medicines called anti-fibrinolytics (medicines to prevent blood loss). Aprotinin can help to reduce blood loss and the need for blood transfusions during isolated cardiopulmonary...
Clinigen Group Plc: Good H1 Performance with Adjusted EPS up 13%
BURTON-ON-TRENT, England--(BUSINESS WIRE)-- Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2017. FINANCIAL SUMMARY Six months ended 31 December 2017 2016 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.